Text written in Basque and translated automatically by Elia without any subsequent editing. SEE ORIGINAL

[Another drug for the treatment of diabetes against obesity]

Drugs such as Semaglutide (Ozempic), Tirzetapide (Mounjaro), etc. were first developed to treat diabetes, but are having great success in the fight against obesity. They have also received the approval of the World Health Organization and, in the clinic, they are becoming, in some cases, the first option. However, they also have unwanted side effects. They are now testing a drug with another target for the same purpose, but without its side effects. Phase II clinical trials have published the results of the first phase in the Cell journal.

“They increase the metabolic activity of skeletal muscle, and with it they also regulate the level of glucose.”

The drugs mentioned at the beginning act on certain intestinal hormones (GLP-1 receptor and the like), which are related to the control of hunger and blood glucose levels, through which the therapeutic effect is achieved. The compounds that are now being tested are beta2 agonists that act on a very different mechanism: the metabolic activity of skeletal muscle. In fact, they increase this activity and, with it, also regulate the level of glucose. And they don’t have the harmful side effects that others have. In addition, they are taken in pills, which also gives them the advantage that the others are injected.

In this first phase, 48 healthy volunteers and 25 people with type 2 diabetes participated with good results. It is now in its second phase.